

K1
iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof.

Please add the following new claim:

K2
-- 50. In a method of NMR imaging a patient comprising administering an NMR contrast agent to said patient, the improvement wherein:

said contrast agent exhibits both renal and extrarenal excretion, and

said contrast agent provides enhanced contrast of the renal system, the gastrointestinal tract and the liver, gall bladder and bile ducts.

51. A method according to claim 50, wherein said NMR contrast agent is administered intravenously. --

REMARKS

Claim 9 is amended to delete compounds in which the group attached to the 4-position is benzyl.

New claim 50 is directed to the method of administering a contrast agent which exhibits both renal and extrarenal excretion which thereby provides enhanced contrast of not only the renal system but also the gastrointestinal tract and the liver, gall bladder and bile ducts. See, for example, the disclosure at page 2, line 7-page 3, line 2.

Respectfully submitted,


Brian P. Heaney (Reg. No. 32,542)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5308
Telefax: (703) 243-6410
Internet Address: heaney@mwzb.com

Filed: April 24, 1997

BPH:kdp
K:\PAT\Sch\1412\sa2.wpd